19 results on '"Fleischhauer, K."'
Search Results
2. Common and well-documented HLA alleles over all of Europe and within European sub-regions: A catalogue from the European Federation for Immunogenetics.
- Author
-
Sanchez‐Mazas, A., Nunes, J. M., Middleton, D., Sauter, J., Buhler, S., McCabe, A., Hofmann, J., Baier, D. M., Schmidt, A. H., Nicoloso, G., Andreani, M., Grubic, Z., Tiercy, J.‐M., and Fleischhauer, K.
- Subjects
HLA histocompatibility antigens ,ALLELES ,EUROPEAN integration ,IMMUNOGENETICS ,HUMAN genetic variation - Abstract
Background A catalogue of common and well-documented (CWD) human leukocyte antigen (HLA), previously established by the American Society for Histocompatibility and Immunogenetics (ASHI), is widely used as indicator for typing ambiguities to be resolved in tissue transplantation or for checking the universality of any HLA allele in the world. However, European population samples, which are characterized by a substantial level of genetic variation, are underrepresented in the ASHI catalogue. Therefore, the Population Genetics Working Group of the European Federation for Immunogenetics (EFI) has facilitated data collection for an European CWD catalogue. Materials and Methods To this end, 2nd-field HLA-A, -B, -C,- DRB1,- DQA1,- DQB1 and -DPB1 data of 77 to 121 European population samples (21 571-3 966 984 individuals) from 3 large databases, HLA-net/ Gene[VA], and DKMS, were analysed. Results The total number of CWD alleles is similar in the EFI (N = 1048) and ASHI (N = 1031) catalogues, but the former counts less common (N = 236 vs 377) and more well-documented (N = 812 vs 654) alleles than the latter, possibly reflecting differences in sample numbers and sizes. Interestingly, approximately half of the CWD alleles reported by EFI were not reported by ASHI and vice-versa, underlining the distinct features of the two catalogues. Also, although 78 common alleles are widely distributed across Europe, some alleles are only common within specific sub-regions, showing regional variability. Conclusion Although the definition of CWD alleles itself is affected by different parameters, calling for current updates of the list, the EFI CWD catalogue provides new insights into European population genetics and will be a very useful tool for tissue-typing laboratories in and beyond Europe. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Common and well-documented HLA alleles: 2012 update to the CWD catalogue.
- Author
-
Mack, S. J., Cano, P., Hollenbach, J. A., He, J., Hurley, C. K., Middleton, D., Moraes, M. E., Pereira, S. E., Kempenich, J. H., Reed, E. F., Setterholm, M., Smith, A. G., Tilanus, M. G., Torres, M., Varney, M. D., Voorter, C. E. M., Fischer, G. F., Fleischhauer, K., Goodridge, D., and Klitz, W.
- Subjects
HLA histocompatibility antigens ,NUCLEOTIDE sequence ,ALLELES ,IMMUNOGENETICS ,BONE marrow ,BIOINFORMATICS ,EMPIRICAL research - Abstract
We have updated the catalogue of common and well-documented ( CWD) human leukocyte antigen ( HLA) alleles to reflect current understanding of the prevalence of specific allele sequences. The original CWD catalogue designated 721 alleles at the HLA-A, -B, -C, - DRB1, - DRB3/4/5, - DQA1, - DQB1, and - DPB1 loci in IMGT (IMmunoGeneTics)/ HLA Database release 2.15.0 as being CWD. The updated CWD catalogue designates 1122 alleles at the HLA-A, -B, -C, - DRB1, - DRB3/4/5, - DQA1, - DQB1, - DPA1 and - DPB1 loci as being CWD, and represents 14.3% of the HLA alleles in IMGT/ HLA Database release 3.9.0. In particular, we identified 415 of these alleles as being 'common' (having known frequencies) and 707 as being 'well-documented' on the basis of ~140,000 sequence-based typing observations and available HLA haplotype data. Using these allele prevalence data, we have also assigned CWD status to specific G and P designations. We identified 147/151 G groups and 290/415 P groups as being CWD. The CWD catalogue will be updated on a regular basis moving forward, and will incorporate changes to the IMGT/ HLA Database as well as empirical data from the histocompatibility and immunogenetics community. This version 2.0.0 of the CWD catalogue is available online at cwd.immunogenomics.org, and will be integrated into the Allele Frequencies Net Database, the IMGT/ HLA Database and National Marrow Donor Program's bioinformatics web pages. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. 16th IHIW: International Histocompatibility Working Group in Hematopoietic Cell Transplantation.
- Author
-
Petersdorf, E. W., Malkki, M., Hsu, K., Bardy, P., Cesbron, A., Dickinson, A., Dubois, V., Fleischhauer, K., Kawase, T., Madrigal, A., Morishima, Y., Shaw, B., Spellman, S., Spierings, E., Stern, M., Tiercy, J.-M., Velardi, A., and Gooley, T.
- Subjects
HEMATOPOIETIC stem cell transplantation ,HISTOCOMPATIBILITY ,HLA histocompatibility antigen genetics ,HAPLOTYPES ,IMMUNOGENETICS ,IMMUNE response - Abstract
The International Histocompatibility Working Group is a collaborative international effort to understand the HLA and non- HLA genetics of the transplantation barrier. The Working Group is comprised of experts in the fields of histocompatibility and immunogenetics, hematopoietic cell transplantation and outcomes research. Data for 25 855 unrelated donor transplants were submitted in support of research studies for the 16th International Histocompatibility Workshop. Active investigation is in progress in seven key areas: the impact of HLA matching, role of race and ethnicity, identification of permissible HLA mismatches, haplotype-associated determinants, minor histocompatibility antigens, immune response genes and KIR genetics. New hypotheses for the 16th workshop were developed for immunogenetic studies in cord blood and haploidentical-related donor transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Genotypes and haplotypes in the 3′ untranslated region of the HLA-G gene and their association with clinical outcome of hematopoietic stem cell transplantation for beta-thalassemia.
- Author
-
Sizzano, F., Testi, M., Zito, L., Crocchiolo, R., Troiano, M., Mazzi, B., Turchiano, G., Torchio, M., Pultrone, C., Gregori, S., Chiesa, R., Gaziev, J., Sodani, P., Marktel, S., Amoroso, A., Roncarolo, M. G., Lucarelli, G., Ciceri, F., Andreani, M., and Fleischhauer, K.
- Subjects
HAPLOTYPES ,HLA histocompatibility antigens ,HEMATOPOIETIC stem cell transplantation ,BETA-Thalassemia ,HEALTH outcome assessment ,GENETIC polymorphisms ,AUTOIMMUNITY - Abstract
Polymorphisms in the 3′ untranslated region (3′UTR) of HLA-G, an important player in immunological tolerance, could be involved in post-transcriptional expression control, and their association with different clinical immune-related conditions including autoimmunity and transplantation is of mounting interest. Most studies have focused on a 14 base pair (bp) insertion/deletion (ins/del), while additional single-nucleotide polymorphisms (SNPs) in the HLA-G 3′UTR have been described but not extensively investigated for their clinical relevance. Here we have comparatively studied the association between 3′UTR haplotypes of HLA-G, or the 14 bp ins/del, with clinical outcome of HLA-identical sibling hematopoietic stem cell transplantation (HSCT) in 147 Middle Eastern beta-thalassemia patients. Sequence based typing of 3′UTR HLA-G polymorphisms in the patients and in 102 healthy Italian blood donors showed strong linkage disequilibrium between the 14 bp ins/del and five 3′UTR SNPs, which together could be arranged into eight distinct haplotypes based on expectation-maximization studies, with four predominant haplotypes (UTRs1-4). After HSCT, we found a moderate though not significant association between the presence of UTR-2 in double dose and protection from acute graft versus host disease (hazard ratio (HR) 0.45, 95% confidence intervals (CI): 0.14-1.45; P = 0.18), an effect that was also seen when the corresponding 14 bp ins/ins genotype was considered alone (HR 0.42, 95% CI: 0.16-1.06; P = 0.07). No association was found with rejection or survival. Taken together, our data show that there is no apparent added value of considering entire 3′UTR HLA-G haplotypes for risk prediction after allogeneic HSCT for beta-thalassemia. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Brief communication Rapid detection of all HLA-B*27 alleles (B*2701–B*2725) by group-specific polymerase chain reaction.
- Author
-
Zino, E., Di Terlizzi, S., Carugo, C., Baggi, L., Galli, A., Bonini, C., Rossini, S., Mazzi, B., and Fleischhauer, K.
- Subjects
ANTIGENS ,RHEUMATISM ,ANKYLOSING spondylitis ,INFECTIOUS arthritis ,IMMUNOSPECIFICITY ,POLYMERASE chain reaction - Abstract
Human leucocyte antigen-B*27 is strongly associated with a number of rheumatic diseases, including ankylosing spondylitis and reactive arthritis. Targeted detection of the B*27 group by molecular methods is hampered by the extreme heterogeneity of the serological B*27 group. Here, we describe a simple, rapid sequence-specific primer-based method for detection of all 28 B*27 alleles defined to date. The method involves an initial screening with two sequence-specific polymerase chain reactions (PCRs), which has to be followed by two additional PCR amplifications in samples carrying a few rare subtypes of B*27, B*4202 or B*7301. The described protocol should be useful for laboratories involved in diagnostics and research of rheumatoid diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
7. Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules.
- Author
-
Fleischhauer, K., Gattinoni, L., Lietti, G., Zino, E., Bordignon, C., and Traversari, C.
- Subjects
- *
LYMPHOCYTES , *CANCER immunotherapy - Abstract
Adoptive immunotherapy of cancer utilizes tumor antigen-specific cytotoxic T lymphocytes (CTL) as mediators of a targeted anti-tumor effect. In this study, we show that such CTL can be able to cross-recognize allogeneic major histocompatibility complex (MHC) molecules in a phenomenon of molecular mimicry. A self histo-leukocyte antigen (HLA) A*0201-restricted CTL specific for peptide MT27-35 from the human differentiation antigen Melan-A/MART-1 was shown to cross-recognize allogeneic A*0220 molecules which differ from syngeneic A*0201 for a single amino acid substi-tution at position 66 of the antigen-binding groove. A*0220 molecules were recognized on a variety of human cells of different histological origin but not on COS-7 cells. A second self-A*0201-restricted CTL, specific for peptide D10/6-271 encoded by the tumor-specific DAM-gene family, was shown to cross-recognize allogeneic B*3701 molecules which differ from syngeneic A*0201 by 32 amino acids in the peptide antigen-binding cleft. B*3701 molecules were recognized on a variety of cell types including COS-7 cells. These data raise new safety issues for clinical trials of cancer immunotherapy using adoptive transfer of in vitro generated, allogeneic CTL with specific anti-tumor activity. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
8. Differential expression of HLA-A*02 subtypes in Colombian Blacks and Mestizos.
- Author
-
Fleischhauer, K., Zino, E., Arevalo-Herrera, M., Herrera, S., Valmori, D., Cerottlni, J.-C., Benazzi, E., Bordignon, C., and Romero, P.
- Published
- 1998
- Full Text
- View/download PDF
9. HLA-A*02 subtype distribution in Caucasians from northern Italy: identification of A*0220.
- Author
-
Fleischhauer, K., Zino, E., Mazzi, B., Severini, G. M., Benazzi, E., and Bordignon, C.
- Published
- 1996
- Full Text
- View/download PDF
10. Follow-up study on PCR-SSOP typing of the HLA-A locus: improved resolution of A-10 and A-19 splits.
- Author
-
Benazzi, E., Zino, E., Mazzi, B., Berti, M., Sironi, E., Bordignon, C., and Fleischhauer, K.
- Published
- 1996
- Full Text
- View/download PDF
11. Complete generic and extensive fine-specificity typing of the HLA-B locus by the PCR-SSOP method.
- Author
-
Fleischhauer, K., Zino, E., Bordignon, C., and Benazzi, E.
- Published
- 1995
- Full Text
- View/download PDF
12. Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain.
- Author
-
Fleischhauer, K., Avila, D., Vilbois, F., Traversari, C., Bordignon, C., and Wallny, H.-J.
- Published
- 1994
- Full Text
- View/download PDF
13. Molecular modelling of HLA-B*35:132.
- Author
-
Longhi, E., Crivello, P., Mantovani, M., Frison, S., Fleischhauer, K., Crespiatico, L., Piccolo, G., and Poli, F.
- Subjects
HLA histocompatibility antigens ,MOLECULAR models ,HISTOCOMPATIBILITY antigens ,T-cell receptor genes ,LEUCINE ,PROLINE ,AMINO acids ,BRANCHED chain amino acids - Abstract
Here we describe the molecular modelling of the new variant HLA- B*35:132. This allele shows one mismatch with B*35:01:01:01 in exon 3 at position 575 where a T is substituted by a C, which implies an amino acidic change from Leucine to Proline. This seems not to alter the molecular structure and not to compromise the HLA complex and T-cell receptor interaction. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Linking allergy to mercury to HLA and burning mouth syndrome.
- Author
-
Pigatto, P. D., Mazzi, B., Fleischhauer, K., and Guzzi, G.
- Subjects
LETTERS to the editor ,ALLERGIES - Abstract
A letter to the editor is presented about a case study hypothesizing that HLA-class II molecules have a role in allergy sensitization to mercury, causing adverse events in oral tissues.
- Published
- 2007
- Full Text
- View/download PDF
15. Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus.
- Author
-
Fleischhauer, K., Agostino, A., Zino, E., Mazzi, B., Benazzi, E., Arevalo-Herrera, M., Herrera, S., Bordignon, C., and Romero, P.
- Subjects
- *
HLA histocompatibility antigens , *HUMAN population genetics , *GENETIC polymorphisms - Abstract
Polymerase chain reaction using sequence-specific oligonucleotide probes (PCR-SSOP) typing was used to analyze HLA class I A, B and C alleles in three different Colombian populations. Fifty-nine samples were from Hispano-American Mestizos living in the urban areas of Cali (referred to here as Aso population). Forty-four and thirty samples were from the African Black populations of Zacarias (Zac) and Punta Soldado (PS), respectively. Samples were selected for expression of HLA-A2 by monoclonal antibody staining and allele-specific hybridization, and their HLA-A2 subtype distribution has been reported previously. Although only a limited number of samples was analyzed, the data suggest the existence of a remarkable degree of HLA class I polymorphism in the populations studied, with representatives of most serological classes. Despite their common African origin, the populations Zac and PS, both resident in malaria endemic regions, showed some striking differences in allelic distribution for all three class I loci. Furthermore, the samples from Aso and PS, but not Zac, showed a low percentage of blank alleles at the HLA-B locus (0 and 0.4%, respectively), suggesting the possibility of a heterozygote advantage for HLA-B alleles in Colombian populations. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
16. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation.
- Author
-
Gagelmann N, Schuh C, Flossdorf S, Kunadt D, Stelljes M, Blau IW, Brecht A, Bethge W, Schroeder T, Wulf G, Sala E, Bug G, Fleischhauer K, and Kröger N
- Subjects
- Humans, Middle Aged, Male, Female, Retrospective Studies, Aged, Adult, Antineoplastic Agents, Alkylating therapeutic use, Antineoplastic Agents, Alkylating administration & dosage, Young Adult, Busulfan analogs & derivatives, Busulfan administration & dosage, Busulfan therapeutic use, Hematopoietic Stem Cell Transplantation, Primary Myelofibrosis therapy, Primary Myelofibrosis mortality, Primary Myelofibrosis drug therapy, Transplantation Conditioning methods, Vidarabine analogs & derivatives, Vidarabine administration & dosage, Vidarabine therapeutic use
- Abstract
One key aspect of allogeneic hematopoietic cell transplantation (HCT) is pretransplant conditioning, balancing risk for relapse versus non-relapse mortality. Conditioning regimens with different alkylators at different doses can influence outcome, but data are missing for myelofibrosis, a challenging cohort of patients usually presenting at older age and with comorbidities. We evaluated in a multicenter retrospective study the comparative efficacy and safety of busulfan versus treosulfan in combination with fludarabine for myelofibrosis patients undergoing HCT. This study included 1115 patients (busulfan, n = 902; treosulfan, n = 213) receiving first HCT between 2005 and 2021. Patients were generally balanced for key patient characteristics. Overall survival at 4 years was 62% for the busulfan group versus 58% for the treosulfan group (p = .22). Impact on outcome was dose-dependent. Overall survival was 65% (95% CI, 61%-69%) for reduced intensity busulfan versus 69% (95% CI, 54%-84%) for reduced intensity treosulfan, 53% (95% CI, 44%-63%) for higher intensity busulfan, and 55% (95% CI, 46%-63%) for higher intensity treosulfan. Incidence of relapse was similar across intensity groups. In multivariable analysis, the hazard for death (with reduced intensity busulfan as reference) was 0.88 (95% CI, 0.39-2.01) for reduced intensity treosulfan (p = .77), 1.42 (95% CI, 0.96-2.10) for higher intensity busulfan (0.08), and 1.61 (95% CI, 1.14-2.26) for higher intensity treosulfan (p = .006). In terms of non-relapse mortality, comparison was not significantly different, while the hazard ratio for higher intensity treosulfan was 1.48 (95% CI, 0.98-2.23; p = .06). Here, we showed comparable outcomes and improved survival in myelofibrosis undergoing HCT with reduced intensity busulfan or treosulfan., (© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
17. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany.
- Author
-
Frietsch JJ, Flossdorf S, Beck JF, Kröger N, Fleischhauer K, Dreger P, Schetelig J, Bornhäuser M, Hochhaus A, and Hilgendorf I
- Subjects
- Child, Adolescent, Humans, Male, Female, Young Adult, Aged, Retrospective Studies, Recurrence, Risk Factors, Tissue Donors, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998-2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event-free and relapse-free survival as well as for the cumulative incidences of non-relapse and therapy-related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post-HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates., (© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
18. Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors.
- Author
-
Merli P, Crivello P, Strocchio L, Pinto RM, Algeri M, Del Bufalo F, Pagliara D, Becilli M, Carta R, Gaspari S, Galaverna F, Quagliarella F, Boz G, Catanoso ML, Boccieri E, Troiano M, Fleischhauer K, Andreani M, and Locatelli F
- Subjects
- Humans, Child, Young Adult, Unrelated Donors, Retrospective Studies, Histocompatibility Testing, Hematopoietic Stem Cell Transplantation adverse effects, Neoplasms etiology, Graft vs Host Disease
- Abstract
High genetic heterogeneity in the human leukocyte antigen (HLA) increases the likelihood of efficient immune response to pathogens and tumours. As measure of HLA diversity, HLA evolutionary divergence (HED) has been shown to predict the response of tumours to immunotherapy and haematopoietic stem cell transplantation (HSCT) in adults. We retrospectively investigated the association of HED with outcomes of 153 paediatric/young adults patients, treated for malignant disorders with HSCT from 9-10/10 HLA-matched unrelated donors. HED was calculated as pairwise genetic distance between alleles in patient HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, using the locus median to stratify patients with 'high' or 'low' HED. Patients with high HED-B and -DRB1 showed significantly improved disease-free survival (DFS), especially when combined (70.8% vs 53.7% p = 0.008). High HED-B + -DRB1 was also associated with improved overall survival (OS) (82.1 vs 66.4% p = 0.014), and concomitant reduction of non-relapse-mortality (5.1% vs 21.1% p = 0.006). The impact on OS and DFS of combined HED-B + -DRB1 was confirmed in multivariate analysis [hazard ratio (HR) 0.39, p = 0.009; and HR 0.45, p = 0.007 respectively]. Only high HED scores for HLA-DPB1 were associated, in univariate analysis, with reduced incidence of relapse (15.9% vs 31.1%, p = 0.03). These results support HED as prognostic marker in allogeneic HSCT and, if confirmed in larger cohorts, would allow its use to inform clinical risk and potentially influence clinical practice., (© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
19. Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution.
- Author
-
Leserer S, Bayraktar E, Trilling M, Bogdanov R, Arrieta-Bolaños E, Tsachakis-Mück N, Crivello P, Koldehoff M, Maaßen F, Ross RS, Fleischhauer K, Beelen DW, and Turki AT
- Subjects
- Adolescent, Adult, Aged, Allografts, Cytomegalovirus physiology, Cytomegalovirus Infections immunology, Female, Follow-Up Studies, Humans, Immune Reconstitution, Kaplan-Meier Estimate, Kinetics, Male, Middle Aged, Proportional Hazards Models, Recurrence, Retrospective Studies, Viremia immunology, Virus Activation, Young Adult, Cytomegalovirus isolation & purification, Cytomegalovirus Infections virology, Hematopoietic Stem Cell Transplantation, Viral Load, Viremia virology
- Abstract
Even in the era of PCR-based monitoring, prophylaxis, and preemptive therapy, Cytomegalovirus (CMV) viremia remains a relevant cause of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT). However, studies using binary analysis (presence/absence of CMV) reported contradicting data for NRM, overall survival and leukemia relapse. Here, we analyzed CMV replication kinetics in 11 508 whole blood PCR samples of 705 patients with HCT between 2012 and 2017. Using two independent models based on CMV peak titers and on the time point of first CMV reactivation, we stratified patients into risk cohorts. Each cohort had distinct cellular immune reconstitution profiles and differentiated for relevant clinical outcomes. Patients with high CMV peak titers had significantly reduced overall survival (HR 2.13, 95% CI 1.53-2.96; p < .0001), due to high NRM. Early impaired T cell reconstitution was a risk factor for high CMV peak titers, however relevant CMV viremia also related to boosted T cell reconstitution. Importantly, intermediate CMV peak titers associated with a significantly reduced relapse probability (HR 0.53, 95% CI 0.31-0.91; p = .022). In short, CMV kinetics models distinguished relevant clinical outcome cohorts beyond the R+ serostatus with distinct immune reconstitution patterns and resolve in part contradicting results of previous studies exclusively focused on the presence or absence of CMV., (© 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.